A retrospective cohort study of gastrografin in the management of adhesive small bowel obstruction during pregnancy

Adhesive small bowel obstruction (ASBO) during pregnancy is extremely dangerous and has not been well researched. The aim of this study was to resolve the difficulties faced in the management of ASBO during pregnancy through the dual role of the diagnosis and treatment of gastrografin. All patients with ASBO during pregnancy whose medical records were retrospectively analyzed between September 2018 and September 2023 were categorized into two groups based on the type of treatment they received: conventional and gastrografin. The two groups did not differ statistically significantly in terms of demographic information, fundamental patient features, or side effects. On the other hand, the gastrografin group outperformed the convention group in terms of improving the rate of success for conservative treatment, lowering the need for surgical procedures, reducing hospital stays, lowering medical costs, and aiding in diagnosis. Gastrografin can be safely used in the pregnant population, where its efficient therapeutic efficacy and accurate diagnostic role are key to resolving the difficulties of ASBO during pregnancy.